OBSERVATIONS

Prevalence of the Metabolic Syndrome in the Elderly Population According to IDF, WHO, and NCEP Definitions and Associations With C-Reactive Protein

The KORA Survey 2000

Recently, the International Diabetes Federation (IDF) has formulated a new worldwide definition for the metabolic syndrome (1). In contrast to the previous World Health Organization (WHO) and National Cholesterol Education Program (NCEP) criteria, abdominal obesity was considered as a prerequisite (2,3). Population-based epidemiological data on the metabolic syndrome in Europe are rare, and the prevalence in Germany is unknown. Thus, we estimated sex-specific prevalences of the metabolic syndrome according to the IDF, WHO, and NCEP definitions in the population-based KORA Survey 2000 (Augsburg, Southern Germany, 711 men and 662 women, age-group 55–74 years) (4). The study was approved by the local ethical committee, and all subjects gave written informed consent.

Among women, 24, 38, and 46% were categorized as having the metabolic syndrome based on the NCEP, WHO, and IDF criteria, respectively. Among men, the prevalence range was even wider (NCEP 28%, WHO 50%, IDF 57%). Overall, agreement between two definitions was moderate (men κ 0.41–0.45, women κ 0.44–0.55). Only 47% of men with IDF-defined metabolic syndrome were insulin resistant (homeostasis model assessment of insulin resistance [HOMA-IR] ≥3.6), as compared with 64 and 61% of those with NCEP- and WHO-defined metabolic syndrome. Similar results were observed in women (IDF 41%, NCEP 52%, WHO 60%).

In men, IDF-defined (odds ratio 1.5 [95% CI 1.05–2.2]), WHO-defined (1.7 [1.3–2.2]), and NCEP-defined (2.0 [1.5–2.5]) metabolic syndrome were significantly associated with the odds of having increased C-reactive protein (≥3 mg/l) in logistic regression adjusting for age, smoking, alcohol intake, physical activity, and educational status. In women, the IDF-defined metabolic syndrome also showed the weakest association with elevated C-reactive protein (IDF 2.8 [2.0–4.1], WHO 3.2 [2.1–4.7], NCEP 3.4 [1.6–7.1]), which persisted when including all three metabolic syndrome criteria in one model.

The metabolic syndrome affects between one-quarter and one-half of the elderly population in Southern Germany, depending on the definition. The higher prevalence of the IDF-defined metabolic syndrome most likely reflects both the lower cutoffs for abdominal obesity and the larger importance given to this risk factor. On the other hand, less than half of those having IDF-defined metabolic syndrome showed insulin resistance according to HOMA-IR, which was lower than the prevalence among those with NCEP- and WHO-defined metabolic syndrome.

In both sexes, the IDF criteria showed a weaker association with the atherosclerosis risk marker C-reactive protein than the other two definitions. Thus, the new IDF metabolic syndrome criteria may possibly lead to a larger misclassification with respect to the future risk of type 2 diabetes or cardiovascular disease in the elderly population than the previous criteria.

Flare-Up of Serum Amylase Prior to Onset of Lethal Ketoadicosis in a Patient With Fulminant Type 1 Diabetes

Fulminant type 1 diabetes has been classified from a traditional type 1 diabetes and characterized by 1) abrupt onset, 2) diabetic ketoacidosis (DKA) at diagnosis, 3) lack of islet-related autoantibodies, 4) elevated pancreatic enzymes, and 5) difficulty in diagnosis during routine screenings (1–4). Flare-ups of some pancreatic exocrine enzymes have been reported for a patient with fulminant type 1 diabetes before DKA onset (3). However, those enzymes are not measured in routine blood analyses.

This report describes a case of fulminant type 1 diabetes with a flare-up of serum amylase before DKA onset, which is easily detectable on routine emergent blood examinations. We discuss the importance of hyperamylasemia at initial diagnosis of the disease.

References

WOLFGANG RATHMANN, MD, MSPH1
BURKHARD HAASTERT, PHD1
ANDREA ICKS, MD, MPH1
GUIDO GIANI, PHD1
ROLF HOLLE, PHD2
WOLFGANG KOENIG, MD3
HANNELORE LÖWEL, MD4
CHRISTA MEISINGER, MD4

From the 1Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Prevention Research and Epidemiology, Düsseldorf, Germany; 2GSF National Research Center for Environment and Health, Institute of Health Sciences, Neuherberg, Germany; 3University of Ulm Medical Center, Ulm, Germany; and 4GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg, Germany.

Address correspondence to Prof. Dr. Wolfgang Koenig, Department of Internal Medicine II, University of Ulm Medical Center, Robert-Kochstr. 8, D-89081 Ulm, Germany. E-mail: wolfgang.koenig@medizin.uni-ulm.de.

© 2006 by the American Diabetes Association.